DESIRE & AROUSAL RESEARCH / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these three peptides.
What is PT-141?
PT-141 is the research-chemical name for bremelanotide, a synthetic cyclic heptapeptide that activates melanocortin receptors — chiefly MC4R — in the hypothalamus. It works centrally on the brain circuits governing sexual desire, not on blood vessels [7]. An FDA-approved pharmaceutical form (bremelanotide injection) was approved in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [5]. Research-grade PT-141 circulates outside the pharmaceutical approval and quality system.
What does the PT-141 peptide do?
In the approved human context, bremelanotide (PT-141) improved sexual desire and reduced desire-related distress in premenopausal women with HSDD across two Phase 3 trials [3]. In a 2022 neuroimaging study, MC4R agonism enhanced amygdala-insula functional connectivity and altered brain processing of erotic stimuli in women with HSDD, providing mechanistic support for a central effect on desire circuits [2]. In animal models it selectively stimulated appetitive sexual behaviors in female rats and produced dose-dependent erections in male rats and nonhuman primates [6][7]. It does not directly raise testosterone and is not a PDE-5 inhibitor.
What is PT-141 used for?
The FDA-approved use for bremelanotide is one specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women [5]. All other uses — including use in men, postmenopausal women, or for general performance enhancement — are off-label. The RECONNECT Phase 3 program enrolled only premenopausal women with HSDD; no Phase 3 data exist for men [3]. Early Phase 2 data in men with erectile dysfunction exist but have not been replicated in adequately powered trials, and one cited salvage study carries an Expression of Concern.
What is kisspeptin?
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene, best known for their role as the master switch of the reproductive hormone axis. The main isoform studied in humans is kisspeptin-54 (also called metastin); kisspeptin-10 is a shorter active fragment. They bind KISS1R (formerly GPR54) on hypothalamic GnRH neurons, triggering pulsatile GnRH release and from there LH, FSH and sex-steroid production [12]. No kisspeptin product is approved for any indication [9]. All human data come from supervised investigational studies.
What does kisspeptin do?
Kisspeptin stimulates the body's own GnRH neurons — it does not supply hormones directly but tells the hypothalamus to release them. The downstream effects include LH and FSH pulses and increased sex-steroid output. In women with hypothalamic amenorrhea, IV kisspeptin-54 restored LH pulsatility [11]; in high-OHSS-risk IVF patients, it triggered oocyte maturation in 95% of women without causing OHSS [10]. In healthy men, kisspeptin-10 bolus raised LH from 4.1 to 12.4 IU/L [12]. Some research also links kisspeptin to sexual motivation at the neural level, paralleling work on the melanocortin desire circuit [2].
Does kisspeptin increase testosterone?
In healthy men, IV kisspeptin-10 at a 4 ug/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L [12]. This is the mechanism: kisspeptin stimulates GnRH release, which drives LH and FSH from the pituitary, which in turn signals the testes to produce testosterone. The effect is therefore indirect — kisspeptin stimulates the axis that produces testosterone, not testosterone itself. Desensitization with repeated dosing means this effect is not reliably sustained with frequent use [11].
How much does kisspeptin increase testosterone?
In healthy men given continuous IV kisspeptin-10 at 4 ug/kg/h, serum testosterone rose from 16.6 to 24.0 nmol/L — roughly a 45% increase in that specific research protocol [12]. Those numbers are from a supervised human pharmacology study using pharmaceutical-grade peptide at specified research doses; they describe what was observed in that protocol, not a general dose-response prediction. The increase fades and may reverse with sustained or repeated dosing due to receptor tachyphylaxis [11]. This site gives no dosing recommendation.
What is Melanotan 2?
Melanotan II (or Melanotan 2) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone, designed at the University of Arizona in the late 1980s. It activates all five melanocortin receptor subtypes (MC1R through MC5R). MC1R activation on melanocytes produces skin darkening; central MC4R activation drives the appetite-suppressing and sexual-arousal effects documented in research [16]. It is distinct from two separately approved melanocortin-related drugs: afamelanotide (approved for a rare skin condition) and bremelanotide / PT-141 (approved for HSDD). Melanotan II itself is not approved by any regulator.
What is Melanotan 2 used for in research?
Melanotan II has been studied for two primary applications: skin tanning (via MC1R) and erectile function (via central MC4R). A 1998 double-blind, placebo-controlled crossover in 10 men with psychogenic erectile dysfunction found it produced clinically apparent erections in 8 of 10 subjects [17]. Its role in the melanocortin peptide lineage — as the structural precursor to bremelanotide (PT-141) — makes it historically important for understanding how the desire-and-arousal research direction developed [16]. It never advanced to late-phase clinical trials for either tanning or sexual function.
How does Melanotan 2 work in the body?
The mechanism branches by receptor subtype. At MC1R on melanocytes, it raises intracellular cAMP, activating the PKA-CREB-MITF cascade that upregulates tyrosinase and produces eumelanin — skin and hair darkening without UV. Central MC4R activation in the hypothalamus drives the sexual-motivation and appetite-suppressing effects. In mice, nucleus-accumbens MC3/4R agonism selectively reduced food consumption and appetitive food-seeking behavior without aversion or metabolic-rate change [14]. The erectogenic effect documented in men is understood as the same central MC4R mechanism that PT-141 later exploited more selectively [17].
Is Melanotan II dangerous?
Melanotan II carries documented serious safety cautions. Case reports describe new or changing moles, eruptive dysplastic nevi, and melanoma in users; dermoscopy studies show measurable melanocytic-lesion changes during use. A case report describes renal infarction; others describe rhabdomyolysis with acute kidney injury and priapism requiring emergency treatment [15]. It is sold without any quality oversight, so actual content of purchased material is unknown. Any new or changing mole during or after use warrants prompt dermatological assessment. Multiple national regulators have issued specific warnings against melanotan products [16].
What is the melanogenesis (MC1R-cAMP-MITF) signaling cascade?
When Melanotan II (or natural alpha-MSH) binds MC1R on melanocytes, it triggers a cascade of intracellular signals: the receptor activates adenylate cyclase, raising cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), which activates the transcription factor CREB. CREB drives expression of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte identity and function. MITF upregulates tyrosinase and related enzymes that synthesize melanin, shifting output toward the dark eumelanin form. The result is skin and hair darkening. This cascade is also the target of the approved drug afamelanotide in erythropoietic protoporphyria — a disease where MC1R stimulation via this cascade offers clinical benefit [16].